ArticleJournal of the American Chemical Society2018
Catch and Release Photosensitizers: Combining Dual-Action Ruthenium Complexes with Protease Inactivation for Targeting Invasive Cancers.
Article in Journal of the American Chemical Society, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 122 citations in OpenAlex.
- Uncaging Iridium(III) Complexes for Combined Photodynamic and Photoactivated Chemotherapy.Angewandte Chemie (International ed. in English) · 2026Article
- Subcellular photochemistry for precision spatial protein targeting.Nature reviews. Chemistry · 2026Review
- In Vivo Imaging of a Photoactivatable Platinum Prodrug by Metal-Centered Radiolabeling.Journal of the American Chemical Society · 2026Article
- Beyond ICACS omega · 2026Article
- Structure over States: Planarity, Not Energy, Dictates Photoactivation in Ru(II) PACT Agents.Journal of the American Chemical Society · 2025Article
- Leveraging the Photofunctions of Transition Metal Complexes for the Design of Innovative Phototherapeutics.Small methods · 2024Review
- Ru(II) Oligothienyl Complexes with Fluorinated Ligands: Photophysical, Electrochemical, and Photobiological Properties.Inorganic chemistry · 2024Article
- Ruthenium-Cathepsin Inhibitor Conjugates for Green Light-Activated Photodynamic Therapy and Photochemotherapy.Inorganic chemistry · 2024Article
- The Impact of Inorganic Systems and Photoactive Metal Compounds on Cytochrome P450 Enzymes and Metabolism: From Induction to Inhibition.Biomolecules · 2024Review
- Ru(II) Phenanthroline-Based Oligothienyl Complexes as Phototherapy Agents.Inorganic chemistry · 2023Article
- Article
- Tricolor visible wavelength-selective photodegradable hydrogel biomaterials.Nature communications · 2023Article
- Cyclic Ruthenium-Peptide Conjugates as Integrin-Targeting Phototherapeutic Prodrugs for the Treatment of Brain Tumors.Journal of the American Chemical Society · 2023Article
- Ligand Rigidity Steers the Selectivity and Efficiency of the Photosubstitution Reaction of Strained Ruthenium Polypyridyl Complexes.Journal of the American Chemical Society · 2023Article
- Hematoporphyrin monomethyl ether mediated photodynamic therapy inhibits oral squamous cell carcinoma by regulating the P53-miR-21-PDCD4 axis via singlet oxygen.Lasers in medical science · 2022Article
- Ru(II) photocages enable precise control over enzyme activity with red light.Nature communications · 2022Article
- Photosubstitution in a trisheteroleptic ruthenium complex inhibits conjunctival melanoma growth in a zebrafish orthotopic xenograft model.Chemical science · 2022Article
- Intraligand Excited States Turn a Ruthenium Oligothiophene Complex into a Light-Triggered Ubertoxin with Anticancer Effects in Extreme Hypoxia.Journal of the American Chemical Society · 2022Article
- Metalloimmunotherapy with Rhodium and Ruthenium Complexes: Targeting Tumor-Associated Macrophages.Chemistry (Weinheim an der Bergstrasse, Germany) · 2022Article
- Photocytotoxicity and photoinduced phosphine ligand exchange in a Ru(ii) polypyridyl complex.Chemical science · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
Abstract
Dual action agents containing a cysteine protease inhibitor and Ru-based photosensitizer for photodynamic therapy (PDT) were designed, synthesized, and validated in 2D culture and 3D functional imaging assays of triple-negative human breast cancer (TNBC). These combination agents deliver and release Ru-based PDT agents to tumor cells and cause cancer cell death upon irradiation with visible light, while at the same time inactivating cathespin B (CTSB), a cysteine protease strongly associated with invasive and metastatic behavior. In total five Ru-based complexes were synthesized with the formula [Ru(bpy)
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.